European expert opinion on the management of invasive candidiasis in adults

• Published in: Clinical microbiology and infection Vol. 17; pp. 1 - 12
• Main Authors: Kullberg, B.J., Verweij, P.E., Akova, M., Arendrup, M.C., Bille, J., Calandra, T., Cuenca-Estrella, M., Herbrecht, R., Jacobs, F., Kalin, M., Kibbler, C.C., Lortholary, O., Martino, P., Meis, J.F., Muñoz, P., Odds, F.C., De Pauw, B.E., Rex, J.H., Roilides, E., Rogers, T.R., Ruhnke, M., Ullmann, A.J., Uzun, Ö., Vandewoude, K., Vincent, J.-L., Donnelly, J.P.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Oxford, UK Elsevier Ltd 01.09.2011; Blackwell Publishing Ltd
• Subjects: Adult; Antibiotic Prophylaxis; Antifungal Agents - therapeutic use; candida; candidaemia; Candidiasis, Invasive - diagnosis; Candidiasis, Invasive - drug therapy; consensus; Europe; guidelines; Humans; Intensive Care Units; Medicin och hälsovetenskap; therapy; Watchful Waiting; Europe; consensus; candidaemia; guidelines; therapy; candida
• ISSN: 1198-743X; 1469-0691; 1469-0691
• DOI: 10.1111/j.1469-0691.2011.03615.x

This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad answering system. After the initial conference, the viewpoint document has been reviewed and edited to include new insights and developments since the initial meeting. For many situations, consensus on treatment could not be reached, and the responses indicate that treatment is likely to be modified on a patient-to-patient basis, depending on factors such as degree of illness, prior exposure to azole antifungals, and the presence of potentially antifungal drug-resistant Candida species.